Treatment of Local Gingival Recession With an Enamel Matrix Protein Coated Collagen Matrix
- Conditions
- Gingival Recession
- Interventions
- Device: Use of coronally advanced flap (CAF) and collagen matrix (CM)Device: Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
- Registration Number
- NCT05799859
- Lead Sponsor
- Medical University of Graz
- Brief Summary
The clinical trial studies patients with gingival recession defects (receding gums).
The goal of the study is to test whether the additional use of enamel matrix derivatives (EMD), combined with the use of a coronally advance flap (CAF) and a CM (collagen matrix), shows a better outcome compared to a comparison group. The comparison group comprises patients receiving treatment with CAF and CM without the use of EMD.
- Detailed Description
The study aims to evaluate the influence of the additional use of EMD in treatment of gingival recession defects using a coronally advance flap (CAF) and a CM (collagen matrix) by means of digital and clinical assessment methods. The reference group comprises patients receiving treatment with CAF and CM without the application of EMD.
In this prospective, randomized, controlled study, recession height and area, width and thickness of keratinized gingiva, pocket probing depth, and the clinical attachment level were measured at baseline and followed-up for one year.
15 patients with 24 gingival recession defects (Recession Type 1 after Cairo/Miller Class I or II) were recruited and were randomly assigned into the two treatment groups.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Signed Informed Consent
- able to achieve good oral hygiene (full mouth plaque score < 20 %, full mouth bleeding score < 20%),
- patients presenting with at least one gingival recession defect
- general contraindications to dental surgery under local anaesthesia (e.g., severe systemic diseases, tumours, severe cardiovascular diseases, uncontrolled diabetes mellitus);
- ongoing or previous chemotherapy, radiotherapy, or bisphosphonate therapy;
- self-reported heavy smokers (more than 10 cigarettes/day);
- pregnancy and nursing mothers;
- disorders or treatments that impair wound healing;
- long-term treatment with high-dose steroids or anticoagulants;
- bone metabolism disorders;
- infections or vascular disorders in the region to be treated;
- known hypersensitivity to porcine collagen;
- patients with severe peripheral artery disease or autoimmune diseases;
- extruded or malpositioned teeth.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CAF + CM Use of coronally advanced flap (CAF) and collagen matrix (CM) Coronally advanced flap (CAF) and collagen matrix (CM) CAF + CM +EMD Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD). Coronally advanced flap (CAF), collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
- Primary Outcome Measures
Name Time Method Gingival recession height 12 months postoperatively Gingival recession height in millimeters, measured as the distance from cementoenamel junction to gingival margin
- Secondary Outcome Measures
Name Time Method pocket probing depth (PPD) 12 months postoperatively Pocket probing depth in millimeters, measured as the distance from gingival margin to bottom of gingival sulcus
Width of keratinized tissue (WKT) 12 months postoperatively Width of keratinized tissue in millimeters, .as distance between gingival margin and muco-gingival junction
Clinical attachment loss (CAL) 12 months postoperatively Clinical attachment loss in millimeters